Prospective Multicenter Registry Study of Multiple System Atrophy in China (MSA Registry S)
Clinical Features and Natural History of Multiple System Atrophy: A Prospective Multicenter Registry Study in China
Multiple system atrophy is a rare, rapidly progressive neurodegenerative disease characterized by variable combinations of parkinsonism, cerebellar ataxia, and autonomic dysfunction. Existing natural history studies from North America, Europe, and Japan suggest that clinical phenotypes and disease progression may differ across populations. However, comprehensive multicenter prospective data from Chinese patients with multiple system atrophy remain limited.
This prospective multicenter registry study aims to describe the clinical characteristics, longitudinal progression, and outcomes of Chinese patients with multiple system atrophy, to identify factors associated with disease progression and prognosis, and to establish a longitudinal cohort for future biomarker validation and clinical trial design.
Studieoversigt
Status
Detaljeret beskrivelse
Multiple system atrophy is an adult-onset, progressive neurodegenerative disorder characterized by parkinsonism, cerebellar ataxia, autonomic dysfunction, and variable non-motor manifestations. The disease is pathologically associated with alpha-synuclein accumulation and neuronal and glial degeneration in multiple brain regions. Due to its rarity, clinical heterogeneity, rapid progression, and poor prognosis, large-scale prospective studies are needed to better define its natural history and to support future therapeutic development.
This study is a prospective, observational, multicenter registry study conducted in China. Eligible participants will include patients with clinically established or clinically probable multiple system atrophy according to the 2022 Movement Disorder Society diagnostic criteria. Parkinson disease patients and healthy or non-neurodegenerative controls may also be enrolled for comparative analyses.
Data will be collected through in-person visits, medical record review, standardized clinical scales, neurological examinations, autonomic function testing, neuroimaging, laboratory tests, and biospecimen collection. Longitudinal follow-up will be performed at prespecified time points, including alternating in-person and telephone-based assessments when applicable. Clinical scales may include the Unified Multiple System Atrophy Rating Scale, Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale, non-motor symptom scales, autonomic symptom scales, and disability measures. Neuroimaging, autonomic function tests, electrophysiological or oculomotor evaluations, and biospecimen-based analyses may be performed according to the study protocol and local clinical practice.
The main objectives are to characterize the clinical features and longitudinal disease course of Chinese patients with multiple system atrophy, compare clinical characteristics between MSA-P and MSA-C subtypes, identify clinical and paraclinical factors associated with disease progression and prognosis, and establish a longitudinal platform for subsequent biomarker validation and clinical trial design.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Yunchuang Sun, MD
- E-mail: sychuang0805@163.com
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100034
- Rekruttering
- Peking University First Hospital
-
Kontakt:
- Yang Zhao
- Telefonnummer: (+86)18610320188
- E-mail: zhaoyang2019@pku.edu.cn
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria
- Patients with clinically established or clinically probable multiple system atrophy according to the 2022 Movement Disorder Society diagnostic criteria; or
- Patients with clinically established or clinically probable Parkinson disease according to the Movement Disorder Society diagnostic criteria; or
- Healthy controls or controls without hereditary or neurodegenerative diseases who voluntarily agree to participate.
- Age between 40 and 75 years.
- Ability to provide informed consent or availability of a legally authorized representative when applicable.
Exclusion Criteria
- Parkinsonism that cannot be classified as Parkinson disease or multiple system atrophy at the time of evaluation.
- Clinical suspicion or diagnosis of other atypical parkinsonian syndromes, including progressive supranuclear palsy, dementia with Lewy bodies, or corticobasal syndrome.
- Secondary parkinsonism due to intracranial space-occupying lesions, normal pressure hydrocephalus, drug-induced parkinsonism, or other identifiable causes.
- Comorbid diseases that may substantially affect autonomic function, such as diabetic peripheral neuropathy or amyloidosis.
- Refusal to participate in the study or refusal to undergo routine clinical evaluations for parkinsonian syndromes.
- Psychiatric or behavioral abnormalities that preclude reliable clinical data collection or scale-based assessment.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
MSA
|
|
PD
|
|
HC
Healthy control / Control without neurodegenerative diseases
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in disease severity
Tidsramme: Baseline to up to 36 months after enrollment.
|
Change in disease severity as measured by the Unified Multiple System Atrophy Rating Scale over longitudinal follow-up.
|
Baseline to up to 36 months after enrollment.
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Zhaoxia Wang, MD, Department of Neurology, Peking University First Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Synukleinopatier
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Patologiske processer
- Sygdomsegenskaber
- Neurodegenerative sygdomme
- Bevægelsesforstyrrelser
- Parkinsonlidelser
- Basal Ganglia Sygdomme
- Primære dysautonomier
- Sygdomme i det autonome nervesystem
- Patologiske tilstande, tegn og symptomer
- Sygdomsprogression
- Parkinsons sygdom
- Multipel systematrofi
- Parkinson Disease 4, Autosomal Dominant Lewy Body
Andre undersøgelses-id-numre
- MSARegistryStudy-20250302
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .